Showing 4621-4630 of 7766 results for "".
- More Positive Results Seen with Endo's Injectable Cellulite Treatmenthttps://practicaldermatology.com/news/more-positive-results-for-endos-injectable-cellulite-treatment/2459965/Endo International plc’s injectable cellulite treatment collagenase clostridium histolyticum ("CCH") showed a clinically meaningful and statistically significant improvement compared to placebo for all primary and secondary endpoints in a Phase 2
- Dermira's Investigational AD Drug Performs Well in Phase 2b Trial, Shares Skyrockethttps://practicaldermatology.com/news/ready-for-phase-3-dermiras-investigational-ad-drug-performs-well-in-phase-2b-trial/2459969/All three doses of Dermira, Inc.’s lebrikizumab showed greater improvements in the Eczema Area and Severity Index in a new Phase 2b dose-ranging study of adults with moderate-to-severe atopic dermatitis, and shares of D
- Study: Port Wine Stain Laser Treatment Is Safe and Effective in Infants Without Anesthesiahttps://practicaldermatology.com/news/study-port-wine-stain-laser-treatment-is-safe-and-effective-in-infants-without-anesthesia/2459974/Recent concerns about the repetitive use of general anesthesia in children younger than 3 have placed greater importance on the controversy surrounding the timing of port-wine stain laser treatment, but a new
- 2019 NewBeauty Awards: Alastin's TransFORM Body Treatment Acknowledged for Innovationhttps://practicaldermatology.com/news/2019-newbeauty-awards-alastins-transform-body-treatment-acknowledged-for-innovation/2459977/ALASTIN Skincare, Inc’s TransFORM Body Treatment has been awarded a 2019 NewBeauty Award in the innovations category. NewBeauty acknowledges the best products, treatments and trends in cosmetics and aesthetics with their innovation category described as, "the future is now
- Almirall: Positive Data for KX2-391 for AKs; ThermiGen to be Divestedhttps://practicaldermatology.com/news/almirall-positive-data-for-kx2-391-for-aks-thermigen-to-be-divested/2459986/Results from two Phase III studies of KX2-391, also known as KX-01 ointment, in the treatment of actinic keratosis show positive results. The findings have been presented at the 2019 American Academy of Dermatology Annual Meeting in Washington, DC and were
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson
- Todd Wood Named DermTech's New Chief Commercial Officerhttps://practicaldermatology.com/news/todd-wood-named-dermtechs-new-chief-commercial-officer/2459883/Todd Wood is DermTech’s new Chief Commercial Officer. Mr. Wood will oversee the Sales and Marketing functions. With 25 years of pharmaceutical and medical device commercialization experience, Mr. Wood has launched multiple market leading product
- Mustela Introduces Skin-Soothing PJs for Eczema-Prone Babies and Toddlershttps://practicaldermatology.com/news/mustela-introduces-skin-soothing-pjs-for-eczema-prone-babies-and-toddlers/2459885/The Global Wellness Institute recently cited smart and healing fashion as one of the biggest trends in wellness, and the new Mustela
- Hoth Therapeutics Names Dr. Adam Friedman to Scientific Advisory Boardhttps://practicaldermatology.com/news/hoth-therapeutics-names-dr-adam-friedman-to-scientific-advisory-board/2459887/Hoth Therapeutics, Inc. has named Adam Friedman, MD to the Company's Scientific Advisory Board. Hoth is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Scientific Adviso